Analysis of Clinical Features and Prognosis in Children with Hodgkin Lymphoma
景晓宇,彭秋雨,何国倩,万智,林超,高举,郭霞
DOI: https://doi.org/10.3760/cma.j.cn511693-20220127-00012
2022-01-01
Abstract:Objective:To summarize the clinical characteristics and prognosis of Hodgkin lymphoma (HL) in children, and analyze the risk factors affecting recurrence/progression in children with HL.Methods:From January 1st, 2008 to December 31st, 2019, a total of 67 HL children in West China Second Hospital of Sichuan University were selected as research subjects. The median onset age of HL children was 9.1 years old (6.0, 11.6 years old), and the male and female children were 52 and 15, respectively. Retrospective analysis was used to collect their clinical data, such as gender, age, tumor invasion site, with group B symptoms, giant mass, pathological type, Ann Arbor stage, risk group, chemotherapy regimen, etc. The constituent ratios of patients with different clinical characteristics were compared with the chi-square test. The Kaplan-Meire method was used to draw curves of overall survival (OS) and event-free survival (EFS). The log-rank test was used for survival rate comparisons of children with different clinical characteristics. Multivariate analysis of factors influencing OS and EFS rate of HL children were performed by Cox proportional hazards model.Multivariate unconditional logistic regression was used to analyze the influencing factors on recurrence/progression in HL children. This study was conducted in accordance with the requirements of the World Medical Association Declaration of Helsinki revised in 2013. Results:① Among the 67 HL children, most of them were males (77.6%, 52/67), aged >7 years (70.1%, 47/67), positive for Epstein-Barr virus (EBV) encoded RNA (EBER) (68.7%, 46/67). The pathological type was predominantly mixed cell types (80.6%, 54/67), the main tumor invasion site was neck (80.6%, 54/67). ② At the end of the second course of chemotherapy, the complete response (CR) rate was 58.2% (39/67), the partial response (PR) rate was 35.8% (24/67), the disease stabilization (SD) rate was 4.5% (3/67), the disease progression (PD) rate was 1.5% (1/67), and the effective rate was 94.0% (63/67). At the end of chemotherapy, 64 children (95.5%) achieved CR, 1 child (1.5%) achieved PR, and 2 children (3.0%) died.③ The median follow-up time was 55.6 months (26.8, 99.4 months). The 5-year OS and EFS rate were 84.6% and 74.4%, respectively. With group B symptoms and incomplete response after initial 2 courses of chemotherapy were independent risk factors influencing OS rate ( OR=11.281, 95% CI: 1.302-97.764, P=0.028; OR=14.091, 95% CI: 1.569-126.573, P=0.018) and EFS rate ( OR=6.470, 95% CI: 1.604-26.104, P=0.009; OR=6.834, 95% CI: 1.810-25.805, P=0.005) in HL children. ④ The proportion of relapse/progression HL children with group B symptoms and incomplete response after initial 2 courses of chemotherapy were 78.6% (11/14) and 100.0% (14/14), respectively, which were significantly higher than those of non-relapsed/progression patients [24.5% (13/53) and 26.4% (14/53)], and the differences were statistically significant( χ2=14.070, 24.651; P<0.001, 0.001). Multivariate unconditional logistic regression analysis showed that with group B symptoms and incomplete response after initial 2 courses of chemotherapy were independent risk factors of relapse/progression in children with HL( OR=6.233, 95% CI: 3.008-13.488, P=0.031; OR=9.403, 95% CI: 2.020-22.832, P<0.001). Conclusions:HL in children is mostly observed in school-aged children and predominantly occurs in male. Children with HL are often accompanied by EBV infection. The pathological type is mainly mixed cell type. Early response to treatment and with group B symptoms can predict the prognosis of children with HL as well as indicate high risk of recurrence/progression.